Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity

Aim. To elucidate therapeutic effect of metformin-sitaglitin combination on the dynamics of indices of insulin resistance and functional activity of pancreaticbeta-cells, lipid metabolism and body weight in patients with type 2 diabetes mellitus (DM2) and obesity. Materials and methods. The study...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alexander Sergeevich Ametov, Elena Nikolaevna Pakus
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2010
Materias:	type 2 diabetes mellitus obesity metformin sitagliptin Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/8ffa4d0318294f518682a1bd04185873
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8ffa4d0318294f518682a1bd04185873
record_format	dspace
spelling	oai:doaj.org-article:8ffa4d0318294f518682a1bd041858732021-11-14T09:00:15ZEfficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity2072-03512072-037810.14341/2072-0351-5490https://doaj.org/article/8ffa4d0318294f518682a1bd041858732010-09-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/5490https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Aim. To elucidate therapeutic effect of metformin-sitaglitin combination on the dynamics of indices of insulin resistance and functional activity of pancreaticbeta-cells, lipid metabolism and body weight in patients with type 2 diabetes mellitus (DM2) and obesity. Materials and methods. The study included 32 patients treated by a combination of metformin (500-2550 mg/day) and sitagliptin (100 mg) for18 weeks. Standard parameters of carbohydrate and lipid metabolism, body mass index (BMI), blood adiponectin and leptin levels were measured, indices of insulin resistance and functional activity of pancreatic beta-cells were calculated. Results. Therapy with metformin-sitagliptin combination ensured compensation of fasting and postprandial hyperglycemia, reduced HbA1c level, increasedfunctional activity of beta-cells, decreased peripheral insulin resistance and BMI, had beneficial effect on lipid metabolism and hormonalactivity of adipose tissue. Conclusion. Metformin-sitagliptin combination can be recommended as a clinically efficacious modality for the treatment of patients with diabetesmellitus and obesity.Alexander Sergeevich AmetovElena Nikolaevna PakusEndocrinology Research Centrearticletype 2 diabetes mellitusobesitymetforminsitagliptinNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 13, Iss 3, Pp 62-65 (2010)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	type 2 diabetes mellitus obesity metformin sitagliptin Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	type 2 diabetes mellitus obesity metformin sitagliptin Nutritional diseases. Deficiency diseases RC620-627 Alexander Sergeevich Ametov Elena Nikolaevna Pakus Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
description	Aim. To elucidate therapeutic effect of metformin-sitaglitin combination on the dynamics of indices of insulin resistance and functional activity of pancreaticbeta-cells, lipid metabolism and body weight in patients with type 2 diabetes mellitus (DM2) and obesity. Materials and methods. The study included 32 patients treated by a combination of metformin (500-2550 mg/day) and sitagliptin (100 mg) for18 weeks. Standard parameters of carbohydrate and lipid metabolism, body mass index (BMI), blood adiponectin and leptin levels were measured, indices of insulin resistance and functional activity of pancreatic beta-cells were calculated. Results. Therapy with metformin-sitagliptin combination ensured compensation of fasting and postprandial hyperglycemia, reduced HbA1c level, increasedfunctional activity of beta-cells, decreased peripheral insulin resistance and BMI, had beneficial effect on lipid metabolism and hormonalactivity of adipose tissue. Conclusion. Metformin-sitagliptin combination can be recommended as a clinically efficacious modality for the treatment of patients with diabetesmellitus and obesity.
format	article
author	Alexander Sergeevich Ametov Elena Nikolaevna Pakus
author_facet	Alexander Sergeevich Ametov Elena Nikolaevna Pakus
author_sort	Alexander Sergeevich Ametov
title	Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
title_short	Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
title_full	Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
title_fullStr	Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
title_full_unstemmed	Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
title_sort	efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
publisher	Endocrinology Research Centre
publishDate	2010
url	https://doaj.org/article/8ffa4d0318294f518682a1bd04185873
work_keys_str_mv	AT alexandersergeevichametov efficacyandsafetyofmetforminsitagliptincombinationforthetreatmentofpatientswithdiabetesmellitusandobesity AT elenanikolaevnapakus efficacyandsafetyofmetforminsitagliptincombinationforthetreatmentofpatientswithdiabetesmellitusandobesity
_version_	1718429668229513216

Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity

Ejemplares similares